Compare Quest Diagnostics Inc (DGX) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Virgin Galactic Holdings, Inc. — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Virgin Galactic Holdings, Inc. trades at $2.63 (market cap $335.48M). The key difference: Quest Diagnostics Inc is far larger — about 68× Virgin Galactic Holdings, Inc.'s market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Virgin Galactic Holdings, Inc. pays none. Which is the better fit depends on your goals.
| DGX | SPCE | |
|---|---|---|
Market Cap | $22.80B | $335.48M |
Sector | Health | Industrials |
52-Week High | $216.02 | $7.52 |
52-Week Low | $166.42 | $2.17 |
Enterprise Value | $28.82B | $435.33M |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
SPCE trades at $2.42, down 5.84% over 24 hours, reflecting ongoing volatility amid negative profitability. The company reported a net loss of $278.91 million on minimal revenue of $1.54 million in 2025, with cash burn persisting despite narrowing losses. Technical indicators are mixed, with a bearish moving average signal but oversold RSI levels, while analyst consensus is divided with a slight hold bias.
The outlook remains speculative, with opportunities tied to future commercial spaceflight execution, but risks are elevated due to persistent losses, high cash burn, and significant debt. Investor sentiment is cautious, driven by the unproven business model and competitive pressures in the space sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
